Acta Scientific MICROBIOLOGY (ISSN: 2581-3226)

Volume 5 Issue 7 July 2022

Short Communication

An Update on Manipulation of Intestinal Microbiota in Halting Avoiding Progression of NAFLD to NASH thus Halting Cirrhosis and HCC Development

Kulvinder Kochar Kaur*

Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India

***Corresponding Author:** Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: May 31, 2022

Published: June 27, 2022

It has been appreciated that what our dietary habits are, besides the diet constituent's are parallel with the manner it is consumed, that has a robust impact on brain health. Over the last 2 decades comprehensive work has been performed for acquisition of insight regarding the key importance of trillions of bacteria that exist in the gastrointestinal tract (GIT) besides the bidirectional crosstalk amongst the heterogenous composition of this large microorganism community as well as opportunity of generation of various diseases like obesity, type 2 diabetes mellitus (T2DM), pain, neurodevelopmental, neurodegenerative as well as neuropsychiatric diseases [1]. An ecosystem comprised of trillions of commensals in the form of bacteria, archaea, protozoa as well as viruses whose collective microbiome is known as microbiota. Further we have reviewed in various studies, it has significance that bidirectional gut-brain dialogue takes place, that represents a complex connection network, apart from part in Non alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH), along with ultimately towards NAFLD associated cirrhosis and Hepatocellular carcinoma (HCC) [2]. Till date numerous clinical along with pre clinical studies have illustrated that NASH patients in general have alterations in their Intestinal microbiota constitutents [3]. Crucial modes are implicated in the control of Intestinal microbiota at the time of NASH propagation. Zhou., *et al*. [4] observed that FMT might improve HFD - stimulated NASH by controlling GM, escalating SCFAs amounts, along with recovering the gut barrier by escalating butyrate and ZO expression. Despite comprehensive work till date no advocated drug is there for these diseases in particular for this greater robust NASH [5,6]. By formation of a spontaneous NAFLD- HCC mouse model by, Odenwald etc. [3], it was revealed that GM dysbiosis helped in NAFLD- HCC production by escalated quantities of, *Mucispirillum, Desulfovibrio, Anaerotruncus* besides *Desulfovibrionaceae,* with reduced *Bacteroides* besides *Bifidobacterium* amounts [3].

Crucial modes have been implicated in the control of Intestinal microbiota at the time of NASH propagation (see figure 1) [7]. Intestinal dysbiosis causes degradation of Intestinal Short chain fatty acids (SCFA), Bile Acids (BA's), choline metabolism homeostasis along with escalated serum lipopolysaccharides (LPS) as well as endogenous ethanol generation besides activation of NLRP 3/6 following which ASNH a). SCFA hamper hepatic steatosis, inflammation besides sustenance of the intactness of the Intestinal barrier b). BA's metabolism is controlled by FXR, along with TRG5 signaling c). Metabolism of choline by intestinal microbiota to TMAO, Nevertheless the impact of TMAO on NASH propagation is surrounded by controversy d). The influence of LPS on NASH propagation implicates mainly toll like receptor 4 (TLR4) as well as nuclear factor κB (NFκB) signaling pathway inclusive of hepatic inflammation, fibrosis as well as liver damage e). Activation of NLRP 3 in in the liver facilitates liver injury however NLRP in the Intestines resulted in sustenance of the Intestinal homeostasis besides recovery of Intestinal dysbiosis. NLRP 3 hampers NASH propagation by hampering TLR4/NFκ B) signaling along with TG accrual besides facilitation of AMP besidesinterleukin-18 (IL-18) liberation f). Intestinal microbiota enhance the generation of endogenous ethanol besides facilitation of NASH propagation [7].

With these contributions greater investigators have tried treatment in NASH patients by therapy that impacts Intestinal

Figure 1: Courtesy ref no-7 - Key mechanisms involved in the regulation of intestinal microbiota during NASH progression. Intestinal dysbiosis results in disruption of intestinal SCFAs, bile acids, and choline metabolic homeostasis, as well as increases LPS and endogenous alcohol production and NLPR3/6 activation, subsequently affecting the progression of ANSH. (A) SCFAs inhibit hepatic steatosis, inflammation, and protect the integrity of the intestinal barrier. Dysbiosis decreases SCFA production, thereby promoting the NASH process. (B) The metabolism of bile acids is regulated by FXR and TGR5. FXR signaling suppresses hepatic steatosis and insulin resistance, as well as negative feedback inhibits bile acid synthesis; TGR5 can protect the liver from inflammation and insulin resistance. However, dysbiosis will reduce the activity of FXR and TGR5 signaling. (C) Intestinal microbiota metabolizes choline to TMAO, but the effect of TMAO on NASH is controversial. (D) LPS mainly affects the progress of NASH through LPS-TLR4 and NF-κB signaling pathways, including hepatic inflammation, fibrosis and liver injury. (E) Activation of NLRP3 in the liver promotes liver damage, but NLRP3 in the intestine maintains intestinal homeostasis and improves intestinal dysbiosis. NLRP6 inhibits NASH progression by inhibiting TLR4/NF-κB signaling and TG accumulation and promoting AMP and IL-18 secretion. (F) Intestinal microbiota increases the production of endogenous alcohol and promotes the progress of NASH. SCFAs, short chain fatty acids; MCT1, monocarboxylate transporter 1; SMCT1, sodium-coupled monocarboxylate transporter 1; AMPK, AMP activated protein kinase; PPARα, Peroxisome proliferator-activated receptor α; GPR41/43, G protein-coupled receptor 41/43; IL-18, Interleukin 18; PYY, peptide YY; GLP1, Glucagon like peptide 1; TLR4, Toll-like Receptor 4; Treg, regulatory T; FXR, Farnesol X receptor; LRH-1, liver receptor homolog 1; CYP7A1, cholesterol 7a hydroxylated enzyme; FGF15/19, fibroblast growth factors 15/19; FGFR4, fibroblast growth factor receptor 4; SREBP-1c, sterol regulatory element-binding protein 1c; TGR5, Takeda G protein-coupled receptor 5; GLP-1R, GLP-1 receptor; NF-κB, nuclear factor - kappaB, TMA, trimethylamine; TMAO, trimethylamine-N-oxide; FMO, flavin monooxygenases; LPS, lipopolysaccharide; LBP, LPS binding protein; TGF-β, transforming growth factor-β; BAMBI, bone morphogenetic protein and active membrane-bound inhibitor; AMPs, antimicrobial peptides; NLRP3/6, nucleotide-binding domain, leucine-rich-repeat containing family, pyrin domain-containing 3/6; TAB2/3, TGF-β activated kinase 1 binding protein 2/3; TG, triglyceride; TCA, tricarboxylic acid.

microbiota with utilization of Probiotics, Prebiotics, along with synbiotics administration, besides Faecal microbiota transplantation (FMT) [8,9].

Prebiotics inclusive of fructooligosaccharides (FOS), oligofructose supplementation represent dietary nonviable food components besides nondigetibled dietary supplements. Prebiotics, cause recovery via selective stimulation of the growth besides activity of the advantageous bacteria. Cani., *et al*. [10] observed that Prebotics enhanced the generation of pro glucagon obtained peptide 2 (GLP2) in ob/ob mice that is followed by reduction in LPS along with reduction of inflammatory along with Oxidative stress (OS) [7]. Other studies have constantly illustrated that FOS mitigates hepatic lipid accrual besides steatohepapititis [7]. In clinical studies Prebiotics have illustrated an attractive effectiveness in the treatment of NASH primarily by reduction of alanine amino transferase (ALT) as well as aspartate amino transferase (AST), besides decreasing hepatic inflammation along with enhancement of *Faecalibacterium prausnitzii (F. prausnitzii) Bifidobacterium*. Synbiotics represent a combination of Probiotics and Prebiotics which hamper NASH significantly with enhancement of liver histological outcomes besides proinflammatory cytokines as well as decreased endotoxin [11]. In a randomized controlled Clinical trial (RCT), Ferolla., *et al*. [12] observed that Synbiotics supplementation caused reduction of hepatic steatosis as well as enhancing, body mass index (BMI) as well as waist circumference (WC). Mechanistically Synbiotics, sub clinically hampered the proinflammatory signaling besides decreased liver fat without changes in prior, Intestinal microbiota. FMT an upcoming method for treating GIT diseases like IBS, Clostridium difficile infection [13]. DM, Unfortunately no studies in NASH done. Zhou., *et al*. [4] observed that FMT might improve HFD- stimulated NASH by controlling GM, enhancing SCFAs amounts, along with recovering the gut barrier by enhancing ZO1 amounts. Hence although promising greater Clinical trials are needed for avoidance of adverse actions besides complications like perforation with FMT.

Bibliography

1. Kulvinder Kochar Kaur., *et al*. "The association of dietary fatty acids and gut microbiota alterations in the development of neuropsychiatric diseases: A systematic review". *Obesity Research - Open Journal* 7.1 (2020): 19-45.

2. Kulvinder Kochar Kaur., *et al*. "An update on the Association of Gut - Liver Axis with Gut Microbiome Dysbiosis Correlated NAFLD along with NAFLD - HCC with Potential Therapeutic Approaches: a systematic review". 2022 - under review Gastroenterology and Hepatology, Lngdom publishers.

3. Song Q and Zhang X. "The role of gut - liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC". *Biomedicine* 10 (2022): 524.

4. Zhou D., *et al*. "Total faecal microbiota transplantation alleviates highfat diet induced non alcoholic steatohepatitis in mice via beneficial regulation of gut microbiota". *Scientific Report* 7 (2017): 1-11.

5. Kulvinder Kochar Kaur., *et al*. "An update on management of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepapititis-Is the time ripe for achieving resolution of NAFLD and NASH soon". *Journal of Endocrinology Research* 3.2 (2021): 44-60.

6. Kulvinder Kochar Kaur., *et al*. "The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity and Metabolic Syndrome –Etiopathogenetic Correlation along with Utilization for Diagnostic and Therapeutic Purposes-A Systematic review". *Journal of Endocrinology Research* 3.2 (2021): 10-34.

7. Xiang H., *et al*. "The role of intestinal microbiota in non alcoholic steatohepatitis". *Frontiers in Endocrinology (Lausanne)* 13 (2022): 8126010.

8. Kulvinder Kochar Kaur., *et al*. "Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review". *Advances in Obesity, Weight Management and Control* 9.1 (2019): 21-28.

9. Kulvinder Kochar Kaur., *et al*. "Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? - A Systematic Review". *Biochemistry and Physiology* 9 (2020): 257.

10. Cani PD., *et al*. "Changes in gut microbiota control inflammation in Obese mice through a Mechanism involving GLP2 driven improvement in Gut permeability". *Gut* 58 (2009): 1091-103.

11. Kobyliac N., *et al*. "A multi strain Probiotic reduces the fatty liver index, cytokines and amino transferase levels: evidence from a randomized Clinical trial". *Journal of Gastrointestinal and Liver Diseases* 27 (2018): 41-49.

12. Ferolla SM., *et al*. "Beneficial effects of symbiotic supplementation on hepatic steatosis and anthropometric parameters but not on Gut permeability in a population of non alcoholic steatohepapititis". *Nutrients* 8 (2016): 397.

13. Kulvinder Kochar Kaur. "Delivered a talk on 30th September on 'Advantages and Limitations of utilizing Clostridium species as Probiotics - A Systematic Review". in a webinar held by Gastroenterology conference on 30th September (2020).